A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.
Carcinoma, Hepatocellular
OTHER: Immunotherapy, targeted therapy.
Progression-Free-Survival, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first., 12 months
To evaluate the efficacy and safety of TACE combined with immunotherapy and targeted therapy in patients with intermediate and advanced liver cancer. Explore the factors affecting the prognosis of liver cancer treated with TACE combined with immunotherapy and targeted therapy and establish a specific individualized prognostic score and risk stratification model.